Health Care Policy and Regulation:
5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impa...
Gespeichert in:
Weitere Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
New York, NY
Springer US
1995
|
Ausgabe: | 1st ed. 1995 |
Schriftenreihe: | Topics in Regulatory Economics and Policy
20 |
Schlagworte: | |
Online-Zugang: | BTU01 Volltext |
Zusammenfassung: | 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns |
Beschreibung: | 1 Online-Ressource (X, 261 p) |
ISBN: | 9781461522195 |
DOI: | 10.1007/978-1-4615-2219-5 |
Internformat
MARC
LEADER | 00000nmm a2200000zcb4500 | ||
---|---|---|---|
001 | BV046872653 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 200828s1995 |||| o||u| ||||||eng d | ||
020 | |a 9781461522195 |9 978-1-4615-2219-5 | ||
024 | 7 | |a 10.1007/978-1-4615-2219-5 |2 doi | |
035 | |a (ZDB-2-SBE)978-1-4615-2219-5 | ||
035 | |a (OCoLC)863673817 | ||
035 | |a (DE-599)BVBBV046872653 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
049 | |a DE-634 | ||
082 | 0 | |a 338.6 |2 23 | |
084 | |a QX 700 |0 (DE-625)142186: |2 rvk | ||
084 | |a QX 705 |0 (DE-625)142187: |2 rvk | ||
245 | 1 | 0 | |a Health Care Policy and Regulation |c edited by Thomas A. Abbott III. |
250 | |a 1st ed. 1995 | ||
264 | 1 | |a New York, NY |b Springer US |c 1995 | |
300 | |a 1 Online-Ressource (X, 261 p) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
490 | 0 | |a Topics in Regulatory Economics and Policy |v 20 | |
520 | |a 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns | ||
650 | 4 | |a Industrial Organization | |
650 | 4 | |a Economic Policy | |
650 | 4 | |a Public Health | |
650 | 4 | |a Industrial organization | |
650 | 4 | |a Economic policy | |
650 | 4 | |a Public health | |
650 | 0 | 7 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Gesundheitswesen |0 (DE-588)4020775-4 |2 gnd |9 rswk-swf |
651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1994 |z New Brunswick NJ |2 gnd-content | |
689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
689 | 0 | 1 | |a Gesundheitswesen |0 (DE-588)4020775-4 |D s |
689 | 0 | 2 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Abbott III, Thomas A. |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461359326 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792395409 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461522201 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-2219-5 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-SBE |a ZDB-2-BAE | ||
940 | 1 | |q ZDB-2-SBE_Archiv | |
999 | |a oai:aleph.bib-bvb.de:BVB01-032282785 | ||
966 | e | |u https://doi.org/10.1007/978-1-4615-2219-5 |l BTU01 |p ZDB-2-SBE |q ZDB-2-SBE_Archiv |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1804181721859489792 |
---|---|
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
author2 | Abbott III, Thomas A. |
author2_role | edt |
author2_variant | i t a a ita itaa |
author_facet | Abbott III, Thomas A. |
building | Verbundindex |
bvnumber | BV046872653 |
classification_rvk | QX 700 QX 705 |
collection | ZDB-2-SBE ZDB-2-BAE |
ctrlnum | (ZDB-2-SBE)978-1-4615-2219-5 (OCoLC)863673817 (DE-599)BVBBV046872653 |
dewey-full | 338.6 |
dewey-hundreds | 300 - Social sciences |
dewey-ones | 338 - Production |
dewey-raw | 338.6 |
dewey-search | 338.6 |
dewey-sort | 3338.6 |
dewey-tens | 330 - Economics |
discipline | Wirtschaftswissenschaften |
discipline_str_mv | Wirtschaftswissenschaften |
doi_str_mv | 10.1007/978-1-4615-2219-5 |
edition | 1st ed. 1995 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03715nmm a2200601zcb4500</leader><controlfield tag="001">BV046872653</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200828s1995 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461522195</subfield><subfield code="9">978-1-4615-2219-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-2219-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBE)978-1-4615-2219-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)863673817</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046872653</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-634</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.6</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QX 700</subfield><subfield code="0">(DE-625)142186:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QX 705</subfield><subfield code="0">(DE-625)142187:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Health Care Policy and Regulation</subfield><subfield code="c">edited by Thomas A. Abbott III.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 1995</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer US</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 261 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Topics in Regulatory Economics and Policy</subfield><subfield code="v">20</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrial Organization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economic Policy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrial organization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economic policy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public health</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitswesen</subfield><subfield code="0">(DE-588)4020775-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1994</subfield><subfield code="z">New Brunswick NJ</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Gesundheitswesen</subfield><subfield code="0">(DE-588)4020775-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abbott III, Thomas A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461359326</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792395409</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461522201</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-2219-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBE</subfield><subfield code="a">ZDB-2-BAE</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBE_Archiv</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032282785</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-2219-5</subfield><subfield code="l">BTU01</subfield><subfield code="p">ZDB-2-SBE</subfield><subfield code="q">ZDB-2-SBE_Archiv</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
genre | (DE-588)1071861417 Konferenzschrift 1994 New Brunswick NJ gnd-content |
genre_facet | Konferenzschrift 1994 New Brunswick NJ |
geographic | USA (DE-588)4078704-7 gnd |
geographic_facet | USA |
id | DE-604.BV046872653 |
illustrated | Not Illustrated |
index_date | 2024-07-03T15:15:37Z |
indexdate | 2024-07-10T08:56:10Z |
institution | BVB |
isbn | 9781461522195 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032282785 |
oclc_num | 863673817 |
open_access_boolean | |
owner | DE-634 |
owner_facet | DE-634 |
physical | 1 Online-Ressource (X, 261 p) |
psigel | ZDB-2-SBE ZDB-2-BAE ZDB-2-SBE_Archiv ZDB-2-SBE ZDB-2-SBE_Archiv |
publishDate | 1995 |
publishDateSearch | 1995 |
publishDateSort | 1995 |
publisher | Springer US |
record_format | marc |
series2 | Topics in Regulatory Economics and Policy |
spelling | Health Care Policy and Regulation edited by Thomas A. Abbott III. 1st ed. 1995 New York, NY Springer US 1995 1 Online-Ressource (X, 261 p) txt rdacontent c rdamedia cr rdacarrier Topics in Regulatory Economics and Policy 20 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns Industrial Organization Economic Policy Public Health Industrial organization Economic policy Public health Gesundheitspolitik (DE-588)4113743-7 gnd rswk-swf Gesundheitswesen (DE-588)4020775-4 gnd rswk-swf USA (DE-588)4078704-7 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1994 New Brunswick NJ gnd-content USA (DE-588)4078704-7 g Gesundheitswesen (DE-588)4020775-4 s Gesundheitspolitik (DE-588)4113743-7 s DE-604 Abbott III, Thomas A. edt Erscheint auch als Druck-Ausgabe 9781461359326 Erscheint auch als Druck-Ausgabe 9780792395409 Erscheint auch als Druck-Ausgabe 9781461522201 https://doi.org/10.1007/978-1-4615-2219-5 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Health Care Policy and Regulation Industrial Organization Economic Policy Public Health Industrial organization Economic policy Public health Gesundheitspolitik (DE-588)4113743-7 gnd Gesundheitswesen (DE-588)4020775-4 gnd |
subject_GND | (DE-588)4113743-7 (DE-588)4020775-4 (DE-588)4078704-7 (DE-588)1071861417 |
title | Health Care Policy and Regulation |
title_auth | Health Care Policy and Regulation |
title_exact_search | Health Care Policy and Regulation |
title_exact_search_txtP | Health Care Policy and Regulation |
title_full | Health Care Policy and Regulation edited by Thomas A. Abbott III. |
title_fullStr | Health Care Policy and Regulation edited by Thomas A. Abbott III. |
title_full_unstemmed | Health Care Policy and Regulation edited by Thomas A. Abbott III. |
title_short | Health Care Policy and Regulation |
title_sort | health care policy and regulation |
topic | Industrial Organization Economic Policy Public Health Industrial organization Economic policy Public health Gesundheitspolitik (DE-588)4113743-7 gnd Gesundheitswesen (DE-588)4020775-4 gnd |
topic_facet | Industrial Organization Economic Policy Public Health Industrial organization Economic policy Public health Gesundheitspolitik Gesundheitswesen USA Konferenzschrift 1994 New Brunswick NJ |
url | https://doi.org/10.1007/978-1-4615-2219-5 |
work_keys_str_mv | AT abbottiiithomasa healthcarepolicyandregulation |